HomeCompareHILS vs JNJ

HILS vs JNJ: Dividend Comparison 2026

HILS yields 843.88% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HILS wins by $4363248.78M in total portfolio value
10 years
HILS
HILS
● Live price
843.88%
Share price
$0.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4363248.80M
Annual income
$3,538,417,394,347.70
Full HILS calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — HILS vs JNJ

📍 HILS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHILSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HILS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HILS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HILS
Annual income on $10K today (after 15% tax)
$71,729.96/yr
After 10yr DRIP, annual income (after tax)
$3,007,654,785,195.55/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, HILS beats the other by $3,007,654,784,491.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HILS + JNJ for your $10,000?

HILS: 50%JNJ: 50%
100% JNJ50/50100% HILS
Portfolio after 10yr
$2181624.41M
Annual income
$1,769,208,697,587.74/yr
Blended yield
81.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HILS
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-0.3
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HILS buys
0
JNJ buys
0
No recent congressional trades found for HILS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHILSJNJ
Forward yield843.88%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$4363248.80M$20.0K
Annual income after 10y$3,538,417,394,347.70$827.78
Total dividends collected$4298592.53M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: HILS vs JNJ ($10,000, DRIP)

YearHILS PortfolioHILS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$95,088$84,388.19$10,676$355.77+$84.4KHILS
2$851,681$749,936.40$11,407$389.39+$840.3KHILS
3$7,188,859$6,277,560.82$12,198$426.53+$7.18MHILS
4$57,213,181$49,521,101.51$13,056$467.62+$57.20MHILS
5$429,552,802$368,334,698.45$13,987$513.12+$429.54MHILS
6$3,044,138,048$2,584,516,550.07$14,998$563.56+$3044.12MHILS
7$20,374,845,574$17,117,617,861.98$16,098$619.52+$20374.83MHILS
8$128,876,441,910$107,075,357,146.57$17,295$681.69+$128876.42MHILS
9$770,870,472,639$632,972,679,795.13$18,599$750.82+$770870.45MHILS
10$4,363,248,800,072$3,538,417,394,347.70$20,022$827.78+$4363248.78MHILS

HILS vs JNJ: Complete Analysis 2026

HILSStock

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Full HILS Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this HILS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HILS vs SCHDHILS vs JEPIHILS vs OHILS vs KOHILS vs MAINHILS vs ABBVHILS vs MRKHILS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.